Vertaling van "involved the risk " (Nederlands → Frans) :

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

This release contains forward-looking information that involves substantial risks and uncertainties concerning the possibility of future dividend increases. Such risks and uncertainties include, among other things, the Company’s future financial performance as well as general economic, political, business, industry, regulatory and market conditions.
Such risks and uncertainties include, among other things, the Company’s future financial performance as well as general economic, political, business, industry, regulatory and market conditions.

This release contains forward-looking information about a potential joint venture between Pfizer and Zhejiang Hisun Pharmaceuticals (Hisun) including, among other things, the anticipated benefits there of, that involves substantial risks and uncertainties.
This information contained in this release is as of June 2, 2011, Pfizer assumes no obligation to update forward-looking statements contaiTned in this release as the result of new information or future events or developments. This release contains forward-looking information about a potential joint venture between Pfizer and Zhejiang Hisun Pharmaceuticals (Hisun) including, among other things, the anticipated benefits there of, that involves substantial risks and uncertainties.

This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines.
DISCLOSURE NOTICE: The information contained in this release is as of December 12, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

At the level of those involved the risk factors that need to be taken into consideration are those regarding the research sites themselves.
At the level of those involved the risk factors that need to be taken into consideration are those regarding the research sites themselves.

Yet, we know that any attempted suicide, even such as do not involve a high medical risk, should be taken seriously, expressing as they do very real distress, i.e. a psychological morbidity that is likely to continue.
Pourtant, nous savons que toute tentative de suicide, même celles ne présentant pas de risque médical important, devrait être prise au sérieux car exprimant une détresse bien réelle, une morbidité psychique risquant de perdurer.

What is more, in some countries, such an admission to a medical facility involves a certain degree of risk, as it may lead to criminal sanctions.
Dans certains pays, ce passage est également risqué dans la mesure où il peut engendrer des sanctions pénales.

However, a fall in the number of RAS incidents originating in Belgium was recorded (30% instead of 47%) ●● The number of class 1 alerts (problems involving life-threatening risks or serious disturbances for the patient) and class 3 alerts (minor deficiencies) remained stable ●● For class 2 alerts (problems that can cause
However, a fall in the number of RAS incidents originating in Belgium was recorded (30% instead of 47%) ●● The number of class 1 alerts (problems involving life-threatening risks or serious disturbances for the patient) and class 3 alerts (minor deficiencies) remained stable ●● For class 2 alerts (problems that can cause

The handling of such applications involves collecting information, risk analysis, suspending distribution and if necessary recall of the medicine.
The handling of such applications involves collecting information, risk analysis, suspending distribution and if necessary recall of the medicine.